Cancer Drug Responses High Point NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Susan Kidwell Williford, MD
(336) 802-2500
302 Westwood Ave
High Point, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1984

Data Provided by:
James F Plowden
(336) 802-2500
302 Westwood Ave
High Point, NC
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Bernard Ravi Chinnasami, MD
(336) 802-2500
302 Westwood Ave
High Point, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Madras Med Coll, Dr M G R Med Univ, Madras, Tn, India
Graduation Year: 1988

Data Provided by:
Bart Alan Frizzell, MD
(336) 878-6036
601 N Elm St
High Point, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Tn, Memphis, Coll Of Med, Memphis Tn 38163
Graduation Year: 1996

Data Provided by:
Peter Robert Ennever
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialty
Hematology, Hematology / Oncology, Medical Oncology

Data Provided by:
James Francis Plowden, MD
(336) 802-2500
302 Westwood Ave
High Point, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Med Univ Of Sc Coll Of Med, Charleston Sc 29425
Graduation Year: 1973
Hospital
Hospital: High Point Regional Hospital, High Point, Nc
Group Practice: Cornerstone Health Care Emerywood

Data Provided by:
Vallathucherry Chakalakumbil Harish
(336) 802-2500
302 Westwood Ave
High Point, NC
Specialty
Hematology / Oncology

Data Provided by:
George Herbert S Sanders, MD
(336) 802-2500
302 Westwood Ave
High Point, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1988

Data Provided by:
Peter Rubin
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialty
Internal Medicine, Medical Oncology

Data Provided by:
Peter Rubin, MD
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Univ Of Calgary, Fac Of Med, Calgary, Alb, Canada
Graduation Year: 1988

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com